This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

9 Mar 2011

Infinity Starts Chondrosarcoma Drug Trial

Infinity Pharmaceuticals announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926.

Infinity Pharmaceuticals has launched a Phase II clinical trial to evaluate IPI-926 as a treatment for patients with metastatic or locally advanced inoperable chondrosarcoma, a rare bone cancer. The randomised, double-blind trial is designed to evaluate the safety and efficacy of IPI-926 compared to placebo, and will enrol more than 100 patients worldwide.


IPI-926 is a novel, oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway.


The primary endpoint of the trial is progression-free survival, while secondary endpoints include time-to-progression, overall survival, overall response rate and response duration.


Related News